Connect with us

Press Releases

Sight Sciences Names 3 Execs

The company focuses on glaucoma and dry eye disease.




Sight Sciences Names 3 Execs

Jim Sluck, Brian Regan and Jessica Holmes

(PRESS RELEASE) MENLO PARK, CA — Sight Sciences Inc., a growth-stage medical device company focused on glaucoma and dry eye disease, announced that Jessica Holmes, Brian Regan and Jim Sluck have joined the company as vice president of health policy and reimbursement, vice president of strategy and professional relations, and vice president of dry eye marketing, respectively. The three industry veterans will bring a wide-range of leadership experience to the management team.

“Sight Sciences has enjoyed substantial growth within the last year, and we see an exciting opportunity to further accelerate growth initiatives across a number of fronts with these strategic additions to our leadership team,” said Paul Badawi, founder and CEO of Sight Sciences. “Jessica, Brian and Jim are thought leaders in their respective domains, and their diverse backgrounds and skill sets will be invaluable in helping us continue to stay true to our mission of addressing the underlying causes of the world’s most prevalent eye diseases with innovative technologies.”

Holmes has more than 25 years of experience in payer and provider relations, government affairs, reimbursement strategy, tactical planning and execution. She has created and executed reimbursement/market access strategies both as a leader within operating companies and as a consultant to commercialize novel technologies in the areas of medical devices, biotechnology, diagnostics, combination products, capital equipment, and durable medical equipment. Previously, Holmes directed the prominent medical device reimbursement and market access practice at Navigant Consulting as director of life sciences and served as vice president of reimbursement for Argenta Advisors Inc. Holmes will be leading the reimbursement and health policy strategy for all of the company’s surgical and dry eye portfolio, ensuring the technologies are accessible to both health care professionals and their patients.

Regan is a highly experienced healthcare operating executive with senior leadership roles focused in marketing, sales and business development at a number of leading medical technology and consumer product companies. Prior to joining Sight Sciences, Regan was vice president of marketing and development at Johnson & Johnson Vision following its acquisition of TearScience Inc. Regan was an executive committee member and marketing organization leader during his more than 10 years with TearScience, and through this work, is considered one of the thought leaders in the development of the evaporative dry eye market. Regan will be leveraging his broad industry experience to lead strategy across both the Surgical and Dry Eye businesses, with a focus on the company’s interactions with key opinion leaders within the ophthalmology and optometry specialties.

Sluck brings more than 30 years of healthcare strategy development and commercial execution experience to Sight Sciences. Prior to joining Sight Sciences, Sluck was part of the market development team at Shire that led the launch and acceleration of Xiidra in the dry eye pharmaceutical market. Before Shire, Sluck held prominent commercial leadership positions at Galderma as vice president of U.S Pharmaceutical Marketing and Alcon in a number of roles, culminating as head of U.S. pharmaceutical marketing. Sluck will be leveraging this significant industry experience to lead the marketing strategy and execution for the launch of TearCare.


With the addition of Sluck, Todd Love will be moving to the vice president of dry eye sales position, leading the company’s dry eye sales force expansion and execution efforts, as well as partnering with Sluck to create a best-in-class launch experience for Sight Sciences’ customers and their patients.



The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines






Get the most important news and business ideas for eyecare professionals every weekday from INVISION.


Most Popular